REGENXBIO Inc.

ROCKVILLE, MD · Biotech · Public

gene therapy platform using NAV capsid technology for delivering therapeutic genes

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · regenxbio.com

Sector
Biotech
Headquarters
ROCKVILLE, MD
Latest Form D
$70.5M, May 2015
Total capital
$106M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$106M
3 Form D · last May 2015
137 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
10
30 pending · first 2024
Rank in peer group#112 of 1449

Capital timeline

201320142015FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$7.9M2nd Form D$27.5M3rd Form D$70.5M
201320142015FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$7.9M2nd Form D$27.5M3rd Form D$70.5M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$70.5M
  • Private capital raisedForm D · SEC · 2nd filing$27.5M
  • Private capital raisedForm D · SEC · 1st filing$7.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#112 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Allan M. FoxDirectorNamed in SEC Form D filings
  • Benjamin T. AuspitzDirectorNamed in SEC Form D filings
  • Camille J. SamuelsDirectorNamed in SEC Form D filings
  • Donald J. Hayden, Jr.DirectorNamed in SEC Form D filings
  • John Daniel KiserDirectorNamed in SEC Form D filings
  • Kenneth T. MillsExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
  • Luke J. BesharDirectorNamed in SEC Form D filings

What it has protected

USPTO · 10 granted of 40
Show all 40 patent records
  • Treatment Of Dystrophinopathies With Microdystrophin Gene Therapy ConstructsOct 20, 2026 · US 12,766,200Granted
  • Systems And Methods Of Spectrophotometry For The Determination Of Genome Content, Capsid Content And Full/empty Ratios Of Adeno-associated Virus ParticlesOct 13, 2026 · US 12,761,144Granted
  • Microdystrophin Nucleic Acid Gene Therapy Constructs And Uses ThereofOct 6, 2026 · US 12,752,020Granted
  • Methods Of Manufacturing Microdystrophin Gene Therapy ConstructsOct 6, 2026 · US 12,752,021Granted
  • Method For Improving Neurological Function In Mpsi And Mpsii And Other Neurological DisordersAug 20, 2026 · Application 19331876Pending
  • Adeno-Associated Virus Vector Formulations and MethodsAug 13, 2026 · Application 19363324Pending
  • Microdystrophin Gene Therapy Constructs And Uses ThereofAug 4, 2026 · US 12,697,399Granted
  • Engineered Nucleic Acid Regulatory Elements And Methods And Uses ThereofMay 14, 2026 · Application 19119083Pending
  • Scalable Method For Recombinant Aav ProductionApr 28, 2026 · US 12,612,644Granted
  • Methods Of Size Exclusion Chromatography For The Characterization Of Recombinant Adeno-associated Virus CompositionsMar 3, 2026 · US 12,565,645Granted
  • Recombinant Adeno-associated Viruses And Uses ThereofFeb 26, 2026 · Application 19105376Pending
  • Compositions For Treatment Of Wet Age-related Macular DegenerationFeb 24, 2026 · US 12,558,434Granted
  • Scalable Clarification Process For Recombinant Aav ProductionFeb 12, 2026 · Application 19258794Pending
  • Vectorized Anti-complement Antibodies And Complement Agents And Administration ThereofFeb 5, 2026 · Application 18862484Pending
  • Pharmaceutical Composition Comprising A Recombinant Adeno-associated Virus Vector With An Expression Cassette Encoding A Transgene For Suprachoroidal AdministrationFeb 5, 2026 · Application 18854403Pending
  • Treatment Of Dystrophinopathies With Microdystrophin Gene Therapy ConstructsDec 4, 2025 · Application 19234245Pending
  • Methods Of Manufacturing Microdystrophin Gene Therapy ConstructsDec 4, 2025 · Application 19234261Pending
  • Microdystrophin Nucleic Acid Gene Therapy Constructs And Uses ThereofDec 4, 2025 · Application 19234243Pending
  • Formulations For Suprachoroidal Administration Such As Formulations With Aggregate FormationNov 6, 2025 · Application 18854315Pending
  • Vectorized Lanadelumab And Administration ThereofOct 23, 2025 · Application 18026117Pending
  • Microdystrophin Gene Therapy Administration For Treatment Of DystrophinopathiesOct 9, 2025 · Application 19245006Pending
  • Vectorized Anti-tnf-alpha Inhibitors For Ocular IndicationsSep 18, 2025 · Application 18862490Pending
  • Fully-human Post-translationally Modified Antibody TherapeuticsSep 4, 2025 · Application 19213663Pending
  • Hybrid Aav CapsidsSep 4, 2025 · Application 18857586Pending
  • Gene Therapy For Treating An Ocular DiseaseAug 7, 2025 · Application 18856534Pending
  • Scalable Clarification Process For Recombinant Aav ProductionJul 22, 2025 · US 12,365,865Granted
  • Compositions And Methods For Recombinant Aav ProductionJul 17, 2025 · Application 18698257Pending
  • Compositions And Methods For Recombinant Aav ProductionJul 3, 2025 · Application 18846499Pending
  • Dominant-negative Tumor Necrosis Factor Alpha Adeno-associated Virus Gene TherapyJul 3, 2025 · Application 18850471Pending
  • Modified Muscle-specific PromotersJun 26, 2025 · Application 18846606Pending
  • Anion Exchange Chromatography For Recombinant Aav ProductionJun 12, 2025 · Application 18777913Pending
  • Recombinant Adeno-associated Viruses For Cns Tropic DeliveryJun 5, 2025 · Application 18697987Pending
  • Injection Of Single-stranded Or Self-complementary Adeno-associated Virus 9 Into The Cerebrospinal FluidMay 1, 2025 · Application 18771234Pending
  • Engineered Nucleic Acid Regulatory Elements And Methods And Uses ThereofJan 23, 2025 · Application 18704628Pending
  • Recombinant Adeno-associated Viruses For Targeted DeliveryJan 2, 2025 · Application 18697964Pending
  • Antibodies And Methods Of Using ThereofDec 26, 2024 · Application 18701201Pending
  • Vectorized Tnf-alpha Antagonists For Ocular IndicationsNov 21, 2024 · Application 18034042Pending
  • Treatment Of Duchenne Muscular Dystrophy And Combinations ThereofOct 31, 2024 · Application 18559078Pending
  • Methods To Treat Mucopolysaccharidosis Type II Or Deficiency In IDURONATE-2-SULFATASE Using A Recombinant Adeno-associated Virus (aav) Vector Encoding IDURONATE-2-SULFATASEOct 22, 2024 · US 12,121,567Granted
  • Methods For Preventing Cardiac Or Skeletal Defects In Diseases Including MucopolysaccharidosesSep 26, 2024 · Application 18264364Pending
  • Synnovation TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Adicet BioSimilar federal contract value in Biotech · null in contracts
  • OPSIDIO, LLCSimilar federal contract value in Biotech · null in contracts
  • SCIBAC INC.Similar federal contract value in Biotech · null in contracts
  • RallybioSimilar federal contract value in Biotech · null in contracts
  • VERSAPEUTICS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .